AXSM
Axsome Therapeutics, Inc.NASDAQHealthcare$168.50-1.91%ClosedMarket Cap: $8.62B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
96.63
P/S
13.50
EV/EBITDA
-51.28
DCF Value
$-563.05
FCF Yield
-1.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.6%
Operating Margin
-26.5%
Net Margin
-28.7%
ROE
-254.1%
ROA
-28.7%
ROIC
-44.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $196.0M | 93.7% | $-29.4M | $-28.6M | $-0.56 | — |
| FY 2025 | $638.5M | 92.6% | $-169.2M | $-183.2M | $-3.68 | — |
| Q3 2025 | $171.0M | 93.0% | $-46.1M | $-47.2M | $-0.94 | — |
| Q2 2025 | $150.0M | 91.0% | $-36.7M | $-48.0M | $-0.97 | — |
| Q1 2025 | $121.5M | 91.9% | $-57.0M | $-59.4M | $-1.22 | — |
| Q4 2024 | $118.8M | 91.1% | $-72.6M | $-74.9M | $-1.54 | — |
| FY 2024 | $385.7M | 91.4% | $-280.6M | $-287.2M | $-5.99 | — |
| Q3 2024 | $104.8M | 91.9% | $-62.6M | $-64.6M | $-1.34 | — |
| Q2 2024 | $87.2M | 90.8% | $-78.0M | $-79.3M | $-1.67 | — |
| Q1 2024 | $75.0M | 91.6% | $-67.3M | $-68.4M | $-1.44 | — |
| Q4 2023 | $71.5M | 89.7% | $-98.3M | $-98.7M | $-2.08 | — |
| FY 2023 | $270.6M | 90.4% | $-231.8M | $-239.2M | $-5.27 | — |